Agenovir Corporation was a biotechnology company founded in 2014 to develop a novel class of human therapeutics targeting diseases caused by latent or persistent viral reservoirs. Built on CRISPR/Cas9 and other nuclease technology from the Stephen Quake lab at Stanford, it designed and simulated nucleases in silico at scale to disrupt… - View it on GitHub